A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
Launched by CARMOT THERAPEUTICS, INC. · Jul 14, 2021
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Part 1: Obese Otherwise Healthy Males
- • Part 2: Males or Females with T2D
- • Part 1: BMI 30.0-35.0, inclusive
- • Part 2: BMI 27.0-45.0, inclusive
- • 18-65 years old, inclusive
- • Stable body weight for 2 months
- Exclusion Criteria:
- • Significant medical history
- • Uncontrolled hypertension
- • History of malignancy
About Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for a range of diseases through its proprietary drug discovery platform. Leveraging advanced chemistry and machine learning, Carmot aims to accelerate the identification and optimization of small molecules that target critical pathways in oncology and other therapeutic areas. Committed to advancing healthcare, the company collaborates with leading academic institutions and industry partners to translate scientific discoveries into novel treatments, ultimately enhancing patient outcomes and addressing unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chula Vista, California, United States
Patients applied
Trial Officials
Clinical Trials
Study Director
Carmot Therapeutics, Inc., a member of the Roche Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials